Ascentage Pharma Group International (AAPG)vsRoyalty Pharma Plc (RPRX)
AAPG
Ascentage Pharma Group International
$18.99
+11.09%
HEALTHCARE · Cap: $1.63B
RPRX
Royalty Pharma Plc
$56.77
-0.86%
HEALTHCARE · Cap: $33.65B
Smart Verdict
WallStSmart Research — data-driven comparison
Royalty Pharma Plc generates 325% more annual revenue ($2.44B vs $574.12M). RPRX leads profitability with a 33.9% profit margin vs -216.5%. RPRX earns a higher WallStSmart Score of 65/100 (C+).
AAPG
Avoid27
out of 100
Grade: F
RPRX
Buy65
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for AAPG.
Margin of Safety
-61.3%
Fair Value
$35.20
Current Price
$56.77
$21.57 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 117.0% year-over-year
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 100.3%
Earnings expanding 23.2% YoY
Generating 1.4B in free cash flow
Areas to Watch
Trading at 9.0x book value
0.0% earnings growth
Smaller company, higher risk/reward
Elevated debt levels
Expensive relative to growth rate
Premium valuation, high expectations priced in
Weak financial health signals
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : AAPG
The strongest argument for AAPG centers on Revenue Growth. Revenue growth of 117.0% demonstrates continued momentum.
Bull Case : RPRX
The strongest argument for RPRX centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 33.9% and operating margin at 100.3%. Revenue growth of 11.0% demonstrates continued momentum.
Bear Case : AAPG
The primary concerns for AAPG are Price/Book, EPS Growth, Market Cap.
Bear Case : RPRX
The primary concerns for RPRX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
AAPG profiles as a hypergrowth stock while RPRX is a mature play — different risk/reward profiles.
AAPG carries more volatility with a beta of 0.66 — expect wider price swings.
AAPG is growing revenue faster at 117.0% — sustainability is the question.
RPRX generates stronger free cash flow (1.4B), providing more financial flexibility.
Bottom Line
RPRX scores higher overall (65/100 vs 27/100), backed by strong 33.9% margins and 11.0% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Ascentage Pharma Group International
HEALTHCARE · BIOTECHNOLOGY · USA
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company is headquartered in Suzhou, China.
Royalty Pharma Plc
HEALTHCARE · BIOTECHNOLOGY · USA
Royalty Pharma plc is a buyer of biopharmaceutical royalties and funder of innovations in the biopharmaceutical industry in the United States. The company is headquartered in New York, New York.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?